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Abstract
Background: The periodontal pathogen Porphyromonas gingivalis is hypothesized to be important in rheumatoid
arthritis (RA) aetiology by inducing production of anti-citrullinated protein antibodies (ACPA). We have shown that
ACPA precede RA onset by years, and that anti-P. gingivalis antibody levels are elevated in RA patients. The aim of
this study was to investigate whether anti-P. gingivalis antibodies pre-date symptom onset and ACPA production.
Methods: A case–control study (251 cases, 198 controls) was performed within the Biobank of Northern Sweden.
Cases had donated blood samples (n = 422) before the onset of RA symptoms by 5.2 (6.2) years (median (interquartile
range)). Blood was also collected from 192 RA patients following diagnosis. Antibodies against P. gingivalis virulence
factor arginine gingipainB (RgpB), and a citrullinated peptide (CPP3) derived from the P. gingivalis peptidylarginine
deiminase enzyme, were analysed by ELISA.
Results: Anti-RgpB IgG levels were significantly increased in pre-symptomatic individuals (mean ± SEM; 152.7 ±
14.8 AU/ml) and in RA patients (114.4 ± 16.9 AU/ml), compared with controls (p < 0.001). Anti-CPP3 antibodies
were detected in 5 % of pre-symptomatic individuals and in 8 % of RA patients, with elevated levels in both subsets
(4.33 ± 0.59 and 9.29 ± 1.81 AU/ml, respectively) compared with controls (p < 0.001). Anti-CPP3 antibodies followed the
ACPA response, with increasing concentrations over time, whilst anti-RgpB antibodies were elevated and stable in the
pre-symptomatic individuals with a trend towards lower levels after RA diagnosis.
Conclusions: Anti-P. gingivalis antibody concentrations were significantly increased in RA patients compared with
controls, and were detectable years before onset of symptoms of RA, supporting an aetiological role for P. gingivalis in
the development of RA.
Keywords: Porphyromonas gingivalis, Antibodies, Arginine gingipainB, Citrullinated peptide, Rheumatoid arthritis,
Predating onset, Anti-citrullinated protein/peptide antibodies
Abbreviations: ACPA, Anti-citrullinated protein/peptide antibodies; anti-CCP, Antibodies against citrullinated peptide
antibodies; CCP1, filaggrin307-324, citrullinated at position 13; anti-CEP-1, antibodies against α-enolase5-21 citrullinated
at positions 9 and 15; anti-cFibβ36-52, antibodies against fibrinogenβ36-52 citrullinated at position 44; AU, Arbitrary
units; CCP, cyclic citrullinated peptide; CI, Confidence interval; CPP3, Cyclic citrullinated peptide 3; ELISA, Enzyme-linked
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immunosorbent assay; HLA, Human leukocyte antigen; IQR, Interquartile range; OR, Odds ratio; PAD, Peptidylarginine
deiminase enzyme; PD, Periodontitis; PTPN22, Protein tyrosine phosphatase non-receptor type 22; RA, Rheumatoid
arthritis; RF, Rheumatoid factor; RgpB, Arginine gingipainB; ROC, Receiver operating characteristic; RPP3, Arginine-
containing control peptide; SD, Standard deviation; SE, Shared epitope; SEM, Standard error of mean
Background
Rheumatoid arthritis (RA), a complex chronic inflamma-
tory disease with a worldwide prevalence of 0.5–1.0 %
[1], is characterized by production of anti-citrullinated
protein/peptide antibodies (ACPA) in the majority of pa-
tients and persistent inflammation in the synovial tissue
of the joints leading to destruction of cartilage and bone
[2–4]. The aetiology of RA remains unknown, although
a complex interplay exists between genetic and environ-
mental factors [5, 6]. Chronic periodontitis (PD), which
is the world’s commonest inflammatory disease often
resulting in destruction of alveolar bone and tooth loss,
has been suggested as an environmental determinant for
the occurrence and severity of RA [7–9].
Elucidation of the potential aetiological link between PD
and RA has progressed [8, 10, 11] and a number of studies
have identified similarities between these two diseases that
possibly explain the epidemiological association. Both
PD and RA display systemic markers of inflammation
(e.g. C-reactive protein and pro-inflammatory cyto-
kines) [6, 12, 13], and an association with HLA-DRB1
alleles [14] and smoking [15, 16] has been described for
both RA and PD. Furthermore, citrullinated proteins
have been detected in both rheumatoid joints and in-
flamed gingival tissue, as well as in other tissues in rela-
tion to inflammatory conditions [17–19]. However, an
association between PD and established RA could not
be confirmed in one of our recent publications [20].
Moreover, data from one of our other studies suggest
that the oral pathogen Porphyromonas gingivalis, rather
than PD, may be linked to the development of RA [21].
P. gingivalis is a common periodontal pathogen associ-
ated with PD [22, 23], and is the only prokaryote known
to express an endogenous peptidylarginine deiminase
enzyme (P.PAD), a virulence factor capable of citrulli-
nating human and bacterial proteins, including auto-
citrullination [24–26]. P.PAD interacts with another
major virulence factor, arginine gingipainB (RgpB), an
arginine-specific extra-cellular protease expressed on the
surface of the bacterial outer membrane [24, 25]. RgpB
is essential for P. gingivalis to citrullinate peptides; that
is, only after degradation by RgpB can P.PAD convert
peptidylarginine into peptidylcitrulline [24, 26].
It is hypothesized that citrullination by P. gingivalis
causes a chronic exposure of citrullinated peptides in the
inflamed periodontium, possibly leading to a break of
immune tolerance in genetically susceptible individuals
and subsequent production of ACPA. Epitope spreading,
induced by molecular mimicry and cross-reactivity with
citrullinated epitopes exposed in the joint, could lead to
progression of chronic RA [27–29]. ACPA appear many
years before the onset of RA [30, 31], suggesting that the
initial immune dysregulation occurs long before symp-
toms of RA develop, outside the joints, potentially at
mucosal sites such as the gingival tissue [17, 27, 32].
Citrullinated P.PAD has been demonstrated to be a tar-
get of the ACPA response [25] and we recently demon-
strated that elevated anti-RgpB antibody levels have a
stronger association with RA than smoking [21], iden-
tifying P. gingivalis as a potential mechanistic link
between PD and RA. Importantly, in the same study we
could also show that anti-RgpB IgG levels were signifi-
cantly increased in sera from PD patients compared
with periodontally healthy individuals, supporting anti-
RgpB IgG as a surrogate marker for oral infection by
P. gingivalis.
This study investigated whether raised anti-P. gingiva-
lis antibody levels precede onset of symptoms of RA and
the ACPA response in order to elucidate the role of P.
gingivalis as a potential trigger of autoimmunity and the
development of RA. Importantly, because we have no
data on periodontal status in our cohorts, we have only
focused on P. gingivalis, not on PD, in the present study.
Consequently, we analysed the antibody response to
RgpB and CPP3, a citrullinated peptide derived from
P.PAD, in blood samples collected prior to the onset of
symptoms and at the diagnosis of RA. Identifying a po-
tential mechanism capable of breaking immunological
tolerance at the earliest stage of disease would provide
an insight into the aetiopathology of RA, and could indi-
cate new clinical therapies and interventions.
Methods
Study population
A case–control study was performed within the Medical
Biobank of Northern Sweden and the Maternity cohort.
The cohorts within the Medical Biobank are population-
based health surveys, and all habitants of Västerbotten
county are continuously invited to participate. Informa-
tion concerning recruitment, blood sampling and storage
conditions has been described previously [30]. The
Maternity cohort is based on blood samples collected
from pregnant women being screened for immunity to
rubella [30]. To identify individuals having donated
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blood samples prior to onset of symptoms of RA, the
register of patients fulfilling the 1987 classification cri-
teria for RA [33] was linked to those of the Medical Bio-
bank and the Maternity cohort.
The study included 251 pre-symptomatic individuals
(58 men/193 women, mean age ± SD 50.5 ± 11.9 years)
who had donated a total of 422 plasma/serum samples
(375 from the Biobank cohorts and 47 from the Mater-
nity cohort) at different time points pre-dating onset of
RA symptoms. From the same cohorts, 198 (31 men/167
women, mean age ± SD 49.3 ± 14.8 years) population-
based controls (173 from the Biobank cohorts and 25
from the Maternity cohort), matched for sex and age,
with sufficient plasma/serum volumes, were identified.
The median time pre-dating the onset of RA symptoms
was 5.2 years (interquartile range 6.2). At least one sam-
ple was identified for each of the 251 pre-symptomatic
individuals; two samples were identified for 92 individ-
uals (36.6 %), three samples for 46 individuals (18.3 %),
four samples for 22 individuals (8.8 %), five samples for
nine individuals (3.6 %) and six samples for two individ-
uals (0.8 %). At the time of RA diagnosis (≤12 months of
symptoms), 192 patients (144 females/48 males) donated
blood samples at the early arthritis clinic. One hundred
and fifty-three of these early RA patients were identified
within the group of pre-symptomatic individuals because
they had donated blood samples before onset of symp-
toms (median 5.6 years, IQR 6.3). Data detailing peri-
odontal status or treatment were not available for these
cases. The participants gave their written informed
consent and the Regional Ethics Committee at Umeå
University approved the study.
Smoking status was defined as ever smoker (including
former and current smokers), current smoker or never
smoker. Because information on being either former or
current smoker was lacking for a number of cases, we
present data for both groups. Of the pre-symptomatic
individuals, 64 % (160/250) were ever smokers and
25.6 % (55/215) were current smokers, while 49.2 % (89/
181) of the controls were ever smokers and 13.1 % (18/
137) were current smokers. HLA-DRB1 shared epitope
(SE) alleles (0101/0401/0404/0405/0408) and PTPN22
1858C/T polymorphism were genotyped as described
previously [34, 35]. Demographic data for the three
groups are presented in Table 1.
Antibody analysis
Using in-house ELISAs as described previously [21, 25],
all plasma/serum samples were analysed blinded for anti-
bodies against the RgpB protein purified from P. gingivalis
[36], a synthetic cyclic citrullinated peptide (CPP3) derived
from P.PAD and the corresponding arginine-containing
control peptide (RPP3) (Innovagen AB, Lund, Sweden).
Serial dilutions of antibody-positive serum pools (anti-
RgpB and anti-CPP3 IgG, respectively) were included on
all ELISA plates to generate standard curves in order to
compare antibody concentrations between cases analysed
on different ELISA plates. All antibody levels are pre-
sented as arbitrary units/ml (AU/ml).
Treating anti-CPP3 IgG as a “classical” ACPA, a cut-off
value for antibody positivity was defined using receiver
operating characteristic (ROC) curves, based on the anti-
CPP3 IgG responses in RA patients and controls. The cut-
off value for positivity was set at >29.19 AU/ml, giving a
specificity of 96 %. No cut-off value could be assigned for
the anti-RgpB IgG response, due to a lack of data regard-
ing PD status of the study subjects.
The plasma/serum samples included in this study had
been analysed previously for the presence of antibodies
against cyclic citrullinated peptides (CCPs), using the
anti-CCP2 ELISA assay (Euro Diagnostica, Malmö,
Sweden), and different ACPA fine specificities (e.g.
cfibrinogenβ36-52 (Fibβ36-52, citrullinated at position
44), α-enolase5-21 (CEP-1, citrullinated at position 9
and 15) and cfilaggrin307-324 (CCP1, citrullinated at
position 13)) using a microarray based on the Immuno-
CAP ISAC system (PhaDia AB, Uppsala, Sweden) [37].
Analysis of rheumatoid factor (RF) of IgM isotype was
performed using the EliA assay on the Phadia 2500-
system according to the manufacturer’s instructions
(Phadia GmbH, Freiburg, Germany). The cut-off value
with the optimum sensitivity and specificity was that
with 96 % specificity.
Table 1 Descriptive data of the pre-symptomatic individuals, patients with RA and controls
Pre-symptomatic individualsa (n = 251) RA patients (n = 192) Controls (n = 198)
Female sex, n (%) 193 (76.9) 144 (75.0) 167 (84.3)
Age, mean ± SD years 50.5 (11.9)b 56.5 (11.3) 49.3 (14.8)
Ever smoker, n (%) 160/250 (64.0) 129 (67.2) 89/181 (49.2)
HLA-DRB1 SE positivec, n (%) 166/250 (66.4) 122/192 (63.5) 61/171 (35.7)
PTPN22 1858 T carrier, n (%) 86/250 (34.4) 63 (32.8) 32/173 (18.5)
aPre-symptomatic individuals were defined as individuals before the onset of symptom of RA
bMean age, as calculated for all samples when collected, pre-symptomatic individuals: n = 422
cHLA-DRB1 shared epitope (SE) alleles were defined as 0101/0401/0404/0405/0408
RA rheumatoid arthritis, SD standard deviation
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Statistical analysis
Continuous data were compared using a non-parametric
Mann–Whitney U-test/Wilcoxon signed rank test in-
cluding two groups, and a Kruskal–Wallis test including
several groups. The chi-square test or Fisher’s exact test
was used when analysing categorical data. Correlation
analysis was performed using Spearman’s rank correl-
ation. Because of the lack of a cut-off value for the anti-
RgpB antibody response, we stratified the anti-RgpB
antibody concentrations into above or below the 75th
percentile in the analyses. Logistic regression analysis
was used to identify associations between antibodies and
risk factors in the development of RA adjusted for age
and sex. Associations were presented as odds ratios
(ORs) with 95 % confidence interval (CI). Standard
methods were used for analysing interactions [38]. All
adjustments were based on previously performed studies
and hypothesis. The statistical analyses were performed
using SPSS 23.0 software (Chicago, IL, USA).
Results
The anti-RgpB antibody response and anti-CPP3 antibody
response in pre-symptomatic individuals, RA patients and
controls
The concentration of anti-RgpB IgG was significantly in-
creased in RA patients (mean ± SEM 114.4 ± 16.9 AU/
ml) and in particular in pre-symptomatic individuals,
calculated using all 422 samples (152.7 ± 14.8 AU/ml) or
one sample per individual (when more than one sample
was available, the sample closest to symptom onset was
chosen) (133.4 ± 16.2 AU/ml; data not shown), compared
with control subjects (82.2 ± 12.1 AU/ml, p < 0.001 for
all three groups) (Fig. 1a).
The anti-CPP3 IgG levels were significantly increased
in RA patients (mean ± SEM 9.29 ± 1.81 AU/ml) com-
pared with pre-symptomatic individuals, both when all
samples were analysed (4.33 ± 0.59 AU/ml) (Fig. 1b) and
when only the sample closest to disease onset was ana-
lysed (5.56 ± 0.89 AU/ml; data not shown); both compari-
sons were analysed at group level (p < 0.001). Antibody
concentrations in both RA patients and pre-symptomatic
individuals were also significantly increased compared
with controls (2.36 ± 0.58 AU/ml, p < 0.001) (Fig. 1b).
The frequency of anti-CPP3 antibodies was 4.5 % in
pre-symptomatic individuals when calculated for all 422
samples, or 6.8 % when calculated for the 251 individ-
uals who were ever positive, and 7.8 % in RA patients
(data not shown). Less than 2 % of all individuals
showed reactivity towards the arginine-containing con-
trol peptide RPP3 (data not shown).
Anti-RgpB IgG levels increased over time until symptom
onset of RA, with a significant increase observed when
analysing individuals with four consecutive pre-dating sam-
ples (p < 0.05; data not shown). There was a trend towards
lower levels following diagnosis of RA (p < 0.088) (Fig. 2a).
Similar to the anti-RgpB IgG response, the levels of anti-
CPP3 IgG were found to increase constantly over the pre-
dating time (Fig. 2a). However, no relationship was found
between anti-CPP3 antibody positivity and the levels of
anti-RgpB IgG (data not shown). The mean concentra-
tion of anti-RgpB antibodies in pre-symptomatic indi-
viduals (n = 64) exceeded that of the controls already
12 years before symptom onset, whilst the correspond-
ing time for anti-CPP3 (n = 126) was 8 years before
symptom onset. However, anti-CPP3 antibody concentra-
tions above the mean value of the controls were detected
in 11 out of 64 (17.2 %) pre-symptomatic individuals more
Fig. 1 Concentrations of anti-RgpB (a) and anti-CPP3 (b) antibodies
in controls, pre-symptomatic individuals and patients with RA. Mean
concentrations marked as a grey line. ***p < 0.001. n.s not significant
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than 10 years before symptom onset. A significantly
higher number of pre-symptomatic individuals (26/64, i.e.
40.6 %) had a concentration of anti-RgpB antibodies above
the mean value of controls at this time point (p < 0.001).
The anti-CPP3 and anti-RgpB antibody response in
relation to the ACPA response
The accumulated frequency of anti-CPP3 antibody
positivity increased constantly over time until symptom
onset (Fig. 2b). This pattern mimics that of the “clas-
sical” ACPA response (defined as antibodies against
CCP2, CEP-1, cFibβ36-52 and cfilaggrin) from the same
time points, although at a lower frequency (Fig. 2b).
The majority of anti-CPP3 IgG-positive RA patients (11
positive/15 analysed) and also pre-symptomatic individ-
uals (11 positive/17 analysed) were confined to the anti-
CCP2-positive subset (Fig. 3a, b, and Additional file 1:
Table S1). In pre-symptomatic individuals, anti-CPP3
positivity was associated with positivity for anti-cFibβ36-
52 antibodies (OR = 3.22; 95 % CI 1.24–8.36, p < 0.05),
and anti-CPP3 antibody levels correlated with the
concentrations of both anti-CCP2 (rs = 0.14, p < 0.01)
and anti-CEP-1 antibodies (rs = 0.11, p < 0.05). The me-
dian pre-dating time for anti-CPP3 antibody positivity
was closer to onset (−3.42 years) compared with anti-
CCP2 (−4.56 years), anti-cFibβ36-52 (−5.17 years) and
anti-CEP-1 (−3.49 years) antibody positivity. There was
also a significant correlation between anti-RgpB IgG
levels and anti-CEP-1 antibodies (rs = 0.10, p < 0.05) in
pre-symptomatic individuals (data not shown). No sig-
nificant relationships were found between anti-RgpB or
anti-CPP3 antibodies, respectively, and RF in the pre-
symptomatic individuals or in RA patients (data not
shown).
Anti-RgpB and anti-CPP3 antibody responses in relation
to cigarette smoking and RA risk genes
No associations were detected between anti-RgpB anti-
body levels and ever smoking in pre-symptomatic individ-
uals, calculated in cases for whom several measurements
were available or for the highest values of anti-RgpB anti-
bodies (data not shown). In RA patients, both ever
Fig. 2 Antibody responses during the pre-dating time until the time point for onset of symptoms of RA, from pre-symptomatic individuals who
donated multiple blood samples pre-dating the onset of symptoms of RA (n = 422) and from patients with RA (n = 192). Logarithmic mean
concentrations during 2-year periods of anti-RgpB and anti-CPP3 antibodies in pre-symptomatic individuals, patients with RA and controls
(n = 198) (a). Accumulated percentages of antibody positivity for anti-CPP3, anti-CCP2, anti-cfibrinogenβ36-52 (cFibβ36-52), anti-CEP-1 (α-enolase) and
anti-cfilaggrin (cFilaggrin) antibodies in pre-symptomatic individuals and in patients with RA (b). 0 time point for onset of RA symptoms
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smoking and current smoking was associated with signifi-
cantly lower levels of anti-RgpB antibodies (p < 0.012 and
p < 0.019, respectively). No associations were identified
between smoking and anti-CPP3 IgG positivity in pre-
symptomatic individuals, or in RA patients (data not
shown). Moreover, no associations were observed be-
tween carriage of HLA-DRB1 SE or PTPN22 T-variant
and levels of anti-RgpB or anti-CPP3 IgG positivity, in
pre-symptomatic individuals. In RA, HLA-DRB1 SE
was unrelated to the antibodies, while the PTPN22 T-
variant was associated with lower levels of anti-RgpB
antibodies (p < 0.05; data not shown). However, caution
should be taken when interpreting these data due to
the low statistical power.
Anti-RgpB and anti-CPP3 antibodies in relation to the
development of RA
An association was identified between anti-RgpB anti-
body levels, stratified for above the 75th percentile vs
below, in pre-symptomatic individuals (OR = 2.31; 95 %
CI 1.41–3.78, p < 0.001) (Table 2). Analyses for ever
smoking or carriage of HLA-DRB1 SE or the PTPN22 T-
variant did not affect the OR (Table 2). Adjustments for
age and sex in each of these analyses did not change the
ORs (data not shown). Levels of anti-RgpB antibodies
were not associated with having RA (OR = 1.20; 95 % CI
0.75–1.92, p = 0.44). Adjustments for smoking or HLA-
DRB1 SE or the PTPN22 T-variant did not affect the as-
sociation between anti-RgpB antibodies and RA
(Table 2), and neither did further adjustments regarding
sex and age (data not shown).
Anti-CPP3 antibodies were not significantly associated
with the development of RA in pre-symptomatic individ-
uals, irrespective of analyses including smoking or HLA-
DRB1 SE or the PTPN22 T-variant (data not shown) or
with further adjustments for sex and age (data not
shown). However, anti-CPP3 IgG was associated with
RA, but only when adjusting for age, sex and HLA-
DRB1 SE (OR = 3.12; 95 % CI 1.06–9.19, p < 0.039) or
the PTPN22 T-variant (OR = 2.96; 95 % CI 1.02–8.57, p
< 0.045) (data not shown). Adjustment for smoking, in
addition to sex and age, was non-significant (OR = 2.66;
95 % CI 0.97–7.26, p = 0.056).
Anti-CPP3 antibodies in combination with smoking or
risk genes in the development of RA
When combining the major genetic risk factor for RA
(HLA-DRB1 SE) with anti-CPP3 IgG positivity, an in-
creasing risk was observed for being pre-symptomatic
(OR = 6.74; 95 % CI 1.43–31.81) compared with HLA-
DRB1 SE-positive/anti-CPP3-negative individuals (OR =
3.55; 95 % CI 2.32–5.42), although no significant inter-
action between the two factors was found (Table 3).
Smoking in combination with anti-CPP3 antibody posi-
tivity showed no association with being pre-symptomatic
(OR = 2.83; 95 % CI 0.86–9.4) (Table 3).
Fig. 3 Pie charts illustrating the different sub-groups of pre-symptomatic
individuals (one sample per individual, n = 251) (a) and RA patients
(n = 188) (b), based on the presence/absence of anti-CCP2 and
anti-CPP3 antibodies. Data presented as percentage
Table 2 Associations between anti-RgpB IgG (stratified for above the 75th percentile vs below) and the development of RA in
pre-symptomatic individuals and RA patients
Pre-symptomatic individuals (n = 251) RA patients (n = 192)
Simple logistic
regression
Multiple logistic regression Simple logistic
regression
Multiple logistic regression
Variable OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
Anti-RgpB 2.31 (1.41–3.78) 2.24 (1.35–3.71) 2.55 (1.67–4.43) 2.17 (1.28–3.68) 1.20 (0.75–1.92) 1.18 (0.73–1.92) 1.30 (0.77–2.17) 1.22 (0.74–2.00)
Ever smoker 1.88 (1.26–2.78) 2.14 (1.41–3.26)
HLA-DRB1 SE 3.58 (2.36–5.42) 3.14 (2.05–4.83)
PTPN22 1858 T-variant 2.17 (1.36–3.48) 2.16 (1.33–3.53)
OR odds ratio, CI confidence interval, RA rheumatoid arthritis
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In RA patients, smoking combined with anti-CPP3
IgG increased the OR significantly from 1.73 (95 % CI
1.10–2.72) in anti-CPP3 IgG-negative ever smokers to
3.61 (95 % CI 1.05–12.44) in anti-CPP3 IgG-positive
ever smokers (Table 4). HLA-DRB1 SE also yielded sig-
nificantly higher OR in combination with anti-CPP3 IgG
positivity than in combination with anti-CPP3 negativity
(OR = 8.80; 95 % CI 1.80–43.03 vs OR = 3.33; 95 % CI
2.11–5.23) (Table 4). However, no significant interac-
tions were observed between smoking and anti-CPP3
IgG, or between SE and anti-CPP3 IgG. Carriage of the
PTPN22 T-variant in combination with anti-CPP3 anti-
body positivity revealed no significant association with
the development of RA in patients or pre-symptomatic
individuals (data not shown). Current smoking yielded
similar results to ever smoking, although slightly weaker
associations, which could be due to fewer current
smokers compared with ever smokers, which also in-
clude former smokers.
Discussion
In the present study we investigated the role of the oral
pathogen P. gingivalis in the development of RA, by fo-
cusing on the anti-P. gingivalis antibody response in RA
patients prior to onset of symptoms. Our recent data
show elevated antibody levels against the potent P. gingi-
valis virulence factor arginine gingipainB in patients
with RA, especially in ACPA-positive RA [21]. We have
Table 3 Association of smoking or HLA-DRB1 SE and anti-CPP3 IgG in pre-symptomatic individuals compared with controls adjusted
for age and sex
Anti-CPP3 IgG Pre-symptomatic individuals, n (%) Controls, n (%) OR (95 % CI)
Smokinga
– – 84 (33.6) 90 (49.7) Reference
+ – 149 (59.6) 85 (47.0) 2.12 (1.39–3.23)
– + 6 (2.4) 2 (1.1) 3.01 (0.58–15.47)
+ + 11 (4.4) 4 (2.2) 2.83 (0.86–9.40)
HLA-DRB1 SEb
– – 79 (31.6) 107 (62.6) Reference
+ – 154 (61.6) 59 (34.5) 3.55 (2.32–5.42)
– + 6 (2.4) 3 (1.8) 2.41 (0.58–10.13)
+ + 11 (4.4) 2 (1.2) 6.74 (1.43–31.81)
RERI = 2.21 (−8.13, 29.19), AP = 0.30 (−3.22, 0.55), SI = 1.52 (0.22–10.90), MI = 0.77 (0.10–6.29), p value = 0.81
aDefined as ever smoker
bHLA-DRB1 shared epitope (SE) defined as 0101/0401/0404/0405/0408
OR odds ratio, CI confidence interval, RERI relative excess due to interaction, AP attributable proportion due to interaction, SI synergy index, MImultiplicative interaction
Table 4 Association of smoking or HLA-DRB1 SE and anti-CPP3 IgG in patients with RA compared with controls adjusted for age
and sex
Anti-CPP3 IgG RA patients, n (%) Controls, n (%) OR (95 % CI)
Smokinga
– – 58 (30.2) 90 (49.7) Ref.
+ – 119 (62.0) 85 (47.0) 1.73 (1.10–2.72)
– + 5 (2.6) 2 (1.1) 4.04 (0.73–22.32)
+ + 10 (5.2) 4 (2.2) 3.61 (1.05–12.44)
RERI = −1.17 (−18.21, 8.19), AP = −0.30 (−7.38, 0.46), SI = 0.71 (0.08–6.55), MI = 0.46 (0.059–3.59), p value = 0.46
HLA-DRB1 SEb
– – 64 (33.3) 107 (62.6)) Ref.
+ – 113 (58.9) 59 (34.5) 3.33 (2.11–5.23)
– + 6 (3.1) 3 (1.8) 3.55 (0.84–15.03)
+ + 9 (4.7) 2 (1.2) 8.80 (1.80–43.03)
RERI = 1.98 (−10.10, 30.25), AP = 0.26 (−3.96, 0.57), SI =1.44 (0.18–11.19), MI = 0.70 (0.08–5.81), p value = 0.74
aDefined as ever smoker
bHLA-DRB1 shared epitope (SE) defined as 0101/0401/0404/0405/0408
OR odds ratio, CI confidence interval, RERI relative excess due to interaction, AP attributable proportion due to interaction, SI synergy index, MI
multiplicative interaction
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also shown that these antibodies are clearly elevated in
patients with PD, compared with periodontally healthy in-
dividuals, demonstrating that anti-RgpB IgG probably
represents a good surrogate marker for P. gingivalis infec-
tion, which has been associated with PD [22, 23]. With the
present study, we report increased concentrations of these
antibodies in a subset of individuals years before onset of
symptoms of RA. Consistent with Quirke et al.’s data in
RA [25], concentrations of anti-CPP3 antibodies directed
against, a synthetic cyclic citrullinated peptide derived
from another P. gingivalis-specific virulence factor, P.PAD,
were also increased in a subset of both pre-symptomatic
individuals and RA patients, compared with controls.
In line with our previous findings in RA patients, the
association between the development of RA in pre-
symptomatic individuals and the anti-RgpB antibody
response was not dependent on smoking habits or pres-
ence of HLA-DRB1 SE or the PTPN22 T-variant [21].
Our data on lower anti-RgpB IgG levels in RA patients
who were ever smokers or current smokers compared
with non-smokers were also in line with a number of
previous reports showing lower anti-P. gingivalis anti-
body levels in smokers compared with non-smokers
[21, 39, 40]. One explanation for the observed trend of
lower anti-RgpB antibody levels in RA patients compared
with pre-symptomatic individuals (Figs. 1a and 2a) could
therefore potentially be the higher frequency of smokers
among RA patients (67.2 %), compared with pre-
symptomatic individuals (64 %). Furthermore, as we re-
cently showed for the anti-RgpB IgG response in RA,
the HLA-DRB1 SE in combination with anti-CPP3 IgG
reveals a stronger association with RA and with being
pre-symptomatic than HLA-DRB1 SE alone. The same
effect occurred when combining smoking with anti-
CPP3 IgG positivity, although only in RA patients, not
in pre-symptomatic individuals.
In this study, stratification of data into ACPA-positive
and ACPA-negative sub-groups was not possible due to
the limited number of individuals. However, a weak correl-
ation between the concentration of anti-RgpB antibodies
and that of the “classical” ACPA, measured as anti-CEP-1
antibodies, could be observed. Notably, ACPA (anti-CEP-1,
anti-cFibβ36-52 and anti-cfilaggrin antibodies) were ana-
lysed by the ISAC multiplex assay, which is only a semi-
quantitative method [37], and thus are not completely
comparable with results from the ELISA used for measur-
ing anti-RgpB IgG.
No relationship was detected between anti-RgpB and
anti-CPP3 antibodies. This was unexpected considering
the origin of both RgpB and CPP3 as P. gingivalis-spe-
cific antigens, and our interpretation of these two anti-
bodies as surrogate markers for a P. gingivalis infection.
Although the concentrations of anti-CPP3 antibodies,
like anti-RgpB antibodies, were significantly increased in
both RA patients and pre-symptomatic individuals com-
pared with controls, the frequency of anti-CPP3 anti-
bodies was only significantly increased in RA patients.
Moreover, the anti-RgpB antibody response was elevated
(compared with controls) several years earlier (12 years)
than the anti-CPP3 antibody response (8 years). The anti-
CPP3 antibody response was similar to the “classical”
ACPA response; that is, there was no reactivity to the
arginine-containing control peptide RPP3, the majority of
anti-CPP3 antibody-positive cases were also anti-CCP2
antibody positive and the anti-CPP3 antibody response
(both concentrations and the accumulated frequency of
positive samples) increased gradually during the
pre-dating time until symptom onset [37]. Taken to-
gether, these data may suggest that the anti-CPP3 anti-
body response, rather than being P. gingivalis specific,
simply belongs to the generic ACPA response, or
rather represents cross-reactivity with another citrulli-
nated antigen. The low frequency of these antibodies
(8 % in RA) could point to this. Moreover, in-vivo
auto-citrullination by P.PAD has been debated [39],
and the CPP3/RPP3 peptide—with its internal rather
than C-terminal citrulline residue—may not represent
an in-vivo-generated antigen. Still, the CPP3/RPP3
peptide sequence is bacterial derived and does not
correspond to any human protein sequence.
Results recently published by Fisher et al. [41] conflict
with ours in that they were unable to identify associations
between anti-RgpB or anti-CPP3 IgG and pre RA. The
two studies differ in several aspects that may explain the
discrepant results: their study was based on a smaller
study population (n = 103) than ours (n = 251, with 422
samples), with participants from a number of different
southern European countries whilst our study subjects
were recruited from a geographically defined area in
northern Sweden; and not all of the pre-symptomatic indi-
viduals in Fisher et al.’s study were confirmed to develop
RA, as they were in our study [41]. Additionally, the peri-
odontal microbiota has been shown to vary between coun-
tries [42] and bacterial strain diversity has been described
previously for P. gingivalis [43]. Altogether, these differ-
ences could contribute to the variability in the results of
these studies.
Supporting our results, Mikuls et al. [44] reported in-
creased concentrations of anti-P. gingivalis antibodies in
high-risk individuals compared with controls. Also in ac-
cordance with our data is a study by de Smit et al. [45],
in which elevated anti-P. gingivalis antibody levels were
observed in arthralgia patients with RF or ACPA positiv-
ity compared with controls. However, anti-P. gingivalis
antibody levels in de Smit et al.’s study were not higher
in arthralgia individuals who developed RA compared
with those who did not. This was not possible to evalu-
ate in our study [45].
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We believe this to be the largest population-based
study analysing the anti-P. gingivalis antibody response
in individuals before onset of symptoms of RA per-
formed to date. Our study has limitations: the samples
analysed were from different population surveys, and
were not collected on a regular basis; no information re-
garding periodontal status or treatment was available,
hence there was an inability to set a cut-off value for the
anti-RgpB antibodies response; and it was not possible
to investigate the relationship between PD and the
development of RA. Also, data on the presence of P.
gingivalis DNA were not available, and analysis of the
anti-RgpB IgG and the anti-CPP3 IgG responses in rela-
tion to the presence of the bacteria was consequently
not possible. However, as in our previous study [21], the
anti-RgpB IgG response was interpreted as a surrogate
marker for a P. gingivalis infection, past or present,
whilst our data suggest that the anti-CPP3 antibody
response, which follows the “classical” ACPA response,
should be considered ACPA specific rather than a P.
gingivalis-specific antibody.
Conclusions
Our data demonstrate that antibodies against P. gingivalis
are significantly increased in patients with RA compared
with controls, and that these antibodies are detectable
years before the onset of symptoms, supporting an
aetiological role for P. gingivalis in the development of
RA. Studies on larger cohorts with samples collected on a
regular basis are needed for a deeper understanding of the
relationship between P. gingivalis, anti-P. gingivalis anti-
bodies, ACPA and the development of RA.
Additional file
Additional file 1: Table S1. Presenting the frequency of ever positivity
for anti-CPP3 antibodies in relation to positive/negative anti-CCP2
antibodies or ACPA. (DOCX 15 kb)
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